SCHEMBL4767723

SCHEMBL4767723

CCOC(=O)c1cnn(Cc2ccccc2C(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.49
ALDH1A1 P00352 2/20 0.49
EPHX2 P34913 7/20 0.43
SCD5 Q86SK9 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA2B P29275 1/20 0.43
ADORA1 P30542 1/20 0.43
PPARG P37231 4/20 0.43
ATM Q13315 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
GAA P10253 1/20 0.43
GRM2 Q14416 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
TAS2R8 Q9NYW2 1/20 0.41
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
JAK3 P52333 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27373753 0.85 GRM2 (0.49) KDM4EALDH1A1EPHX2PPARGGAA
SCHEMBL3096725 0.84 ALDH1A1 (0.56) KDM4EALDH1A1SCD5NPSR1GAA
SCHEMBL27286280 0.84 MAOA (0.49) KDM4EALDH1A1EPHX2SCD5ADORA2A
SCHEMBL28760613 0.83 EPHX2 (0.51) KDM4EALDH1A1EPHX2SCD5ADORA2A
SCHEMBL30482323 0.82 MAOB (0.49) KDM4EALDH1A1EPHX2SCD5ADORA2A
SCHEMBL3606815 0.80 MAPT (0.46) KDM4EALDH1A1TDP1GRM2MEN1
SCHEMBL30736841 0.80 CRHBP (0.44) ALDH1A1GRM2KMT2A
SCHEMBL30739039 0.79 GRM2 (0.40) KDM4EALDH1A1GRM2MEN1KMT2A
SCHEMBL29058607 0.79 GRM2 (0.42) KDM4EALDH1A1GAAGRM2MEN1
SCHEMBL1198218 0.79 L3MBTL1 (0.47) KDM4EALDH1A1NPSR1TDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1678181-B1 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS INC (US) 2008-12-31 EP disclosed
US-7449473-B2 Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2008-11-11 US disclosed
EP-1678181-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2006-07-12 EP disclosed
US-20050119287-A1 A2B adenosine receptor antagonists GILEAD PALO ALTO, INC. 2005-06-02 US disclosed
WO-2005042534-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119287-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA3 KDM4E 3386/4885ALDH1A1 1178/4885EPHX2 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.